Skip to main content
Top

03-02-2018 | Osteoporosis | Article

FRAX calculated without BMD does not correctly identify Caucasian men with densitometric evidence of osteoporosis

Journal: Osteoporosis International

Authors: R. C. Hamdy, E. Seier, K. Whalen, W. A. Clark, K. Hicks, T. B. Piggee

Publisher: Springer London

Abstract

Summary

The FRAX algorithm assesses the patient’s probability of sustaining an osteoporotic fracture and can be calculated with or without densitometric data. This study seeks to determine whether in men, FRAX scores calculated without BMD, correctly identify patients with BMD-defined osteoporosis.

Introduction

The diagnosis of osteoporosis is based on densitometric data, the presence of a fragility fracture or increased fracture risk. The FRAX algorithm estimates the patient’s 10-year probability of sustaining an osteoporotic fracture and can be calculated with or without BMD data. The purpose of this study is to determine whether in men, FRAX calculated without BMD, can correctly identify patients with BMD-defined osteoporosis.

Methods

Retrospectively retrieved data from 726 consecutive Caucasian males, 50 to 70 years old referred to our Osteoporosis Center.

Results

In the population studied, 11.8 and 25.3% had BMD-defined osteoporosis when female and male reference populations were used respectively. When the National Osteoporosis Foundation thresholds to initiate treatment are used, only 27% of patients with BMD-defined osteoporosis, but 4% with normal BMD reached/exceeded these thresholds. Lowering the threshold increased sensitivity, but decreased specificity.

Conclusions

Our results suggest that FRAX without BMD is not sensitive/specific enough to be used to identify Caucasian men 50 to 70 years old with BMD-defined osteoporosis.
Literature
1.
NIH Consensus Development Panel on Osteoporosis Prevention (2001) Diagnosis and therapy. JAMA 285(6):785–795. https://​doi.​org/​10.​1001/​jama.​285.​6.​785 CrossRef
2.
Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren l, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108–1112. https://​doi.​org/​10.​1001/​archinte.​164.​10.​1108 CrossRefPubMed
3.
Siris ES, Adler R, Bilezekian JP et al (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443CrossRefPubMedPubMedCentral
4.
Kanis JA (2013) FRAX®: assessment of fracture risk. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Eighth Edition, pp 289–296. https://​doi.​org/​10.​1002/​9781118453926.​ch34 CrossRef
5.
Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Assessment of fracture risk. Eur J Radiol 71(3):392–397. https://​doi.​org/​10.​1016/​j.​ejrad.​2008.​04.​061 CrossRefPubMed
6.
National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington www.​nof.​org
7.
Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 ISCD position development conference on bone densitometry. JCD 16(4):455–467. https://​doi.​org/​10.​1016/​j.​jocd.​2013.​08.​004 CrossRef
8.
US Preventive Services Task Force (2011) Screening for osteoporosis: US Preventive Services Task Force recommendation statement. Ann Intern Med 154:356–364CrossRef
9.
Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV (2010) Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int 21(5):863–871. https://​doi.​org/​10.​1007/​s00198-009-1026-7 CrossRefPubMed
10.
Bolland MJ, Siu AT, Mason BH et al (2011) Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 26(2):420–427. https://​doi.​org/​10.​1002/​jbmr.​215 CrossRefPubMed
11.
Kuruvilla K, Kenny AM, Raisz LG, Kerstetter JE, Feinn RS, Rajan TV (2011) Importance of bone mineral density measurements in evaluating fragility bone fracture risk in Asian Indian men. Osteoporos Int 22(1):217–221. https://​doi.​org/​10.​1007/​s00198-010-1237-y CrossRefPubMed
12.
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: fracture intervention trial – FIT. J Clin Endocrinol Metab 85(11):4118–4124. https://​doi.​org/​10.​1210/​jcem.​85.​11.​6953 CrossRefPubMed
13.
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340CrossRefPubMed
14.
Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249CrossRefPubMed
15.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. https://​doi.​org/​10.​1056/​NEJMoa067312 CrossRefPubMed
16.
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and BMD in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. https://​doi.​org/​10.​1056/​NEJM200105103441​904 CrossRefPubMed
17.
Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed
18.
Chesnut CH III, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109(4):267–276CrossRefPubMed
19.
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE). JAMA 282(7):637–645. https://​doi.​org/​10.​1001/​jama.​282.​7.​637 CrossRefPubMed
20.
Austin M, Yand Y-C, Vittinghoff E et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27(3):687–693. https://​doi.​org/​10.​1002/​jbmr.​1472 CrossRefPubMedPubMedCentral
21.
Small RE (2005) Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 7(2):3–12PubMedPubMedCentral
22.
Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, National Osteoporosis Guideline Group (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392–396. https://​doi.​org/​10.​1016/​j.​maturitas.​2013.​05.​013 CrossRefPubMed
23.
Kanis JA, McCloskey EV, Johansson H et al (2013) European Guidance for the Diagnosis and Management of Osteoporosis in postmenopausal women. Osteoporosis Int 24(1):23–57. https://​doi.​org/​10.​1007/​s00198-012-2074-y CrossRef
24.
Cauley JA, Fuleihan GE, Arabi A et al (2011) Official positions for FRAX clinical regarding international differences. J Clin Densitom 14(3):240–262. https://​doi.​org/​10.​1016/​j.​jocd.​2011.​05.​015 CrossRefPubMed